Clinical Trial Update: Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme [Phase 1]

View source ↗

Summary

Phase 1 safety study of tandutinib in combination with temozolomide and bevacizumab for newly diagnosed glioblastoma; the trial has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Avastin (bevacizumab)
• Tandutinib (tandutinib)
• Temodar (Temozolomide)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Glioblastoma Multiforme | Phase 1 | Status: WITHDRAWN